Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
IVX-A12 · 2 trials · 2 indications
| Name | Type | Description |
|---|---|---|
| IVX-A12 | BIOLOGICAL | IVX-A12 IM injection. |
| Licensed RSV Vaccine | BIOLOGICAL | Licensed RSV Vaccine (AREXVY) IM injection. |
| Placebo | BIOLOGICAL | Diluent |
IVX-A12 is an investigational monoclonal antibody being studied in healthy participants and healthy adults. It is currently in Phase 2 clinical development, with completed trials evaluating its safety and immunogenicity in adults aged 60 to 85 years and in adult participants.
IVX-A12 is being developed by AstraZeneca PLC, a biopharmaceutical company listed on the stock exchange under the ticker symbol AZN. The company is conducting clinical trials to evaluate the safety and immunogenicity of this investigational monoclonal antibody.
IVX-A12 is in Phase 2 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still undergoing clinical trials to assess its safety and immunogenicity in healthy participants.
IVX-A12 has been studied in two completed Phase 2 trials. The first, NCT05903183, evaluated safety and immunogenicity in 264 participants aged 60 to 85 years. The second, NCT06481579, studied IVX-A12 in 143 adult participants. Both trials enrolled healthy individuals.
Yes, IVX-A12 is a monoclonal antibody. It is being developed by AstraZeneca PLC as an investigational therapy for healthy participants, with Phase 2 trials completed to evaluate its safety and immunogenicity.